Cytori Therapeutics (CYTX) Stock Price Down 6.2%

Cytori Therapeutics Inc (NASDAQ:CYTX) fell 6.2% on Tuesday . The company traded as low as $0.30 and last traded at $0.28. 791,240 shares changed hands during trading, an increase of 2% from the average session volume of 777,109 shares. The stock had previously closed at $0.30.

A number of brokerages recently weighed in on CYTX. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a research report on Friday, August 11th. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th.

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. The firm had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. During the same quarter in the previous year, the company posted ($0.26) EPS. sell-side analysts predict that Cytori Therapeutics Inc will post -0.62 EPS for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC grew its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,626,807 shares of the biotechnology company’s stock after purchasing an additional 355,504 shares during the quarter. Sabby Management LLC owned about 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 7.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply